advertisement

---

Wolf AT 9

Showing records 1 to 9 | Display all abstracts from Wolf AT

98167 Vascular biomarkers from optical coherence tomography angiography and glaucoma: where do we stand in 2021?
Shin JD
Acta Ophthalmologica 2022; 100: e377-e385

---

98596 Disease progression pathways of wet AMD: opportunities for new target discovery
Wolf AT; Wolf AT; Harris A
Expert Opinion on Therapeutic Targets 2022; 26: 5-12

---

98167 Vascular biomarkers from optical coherence tomography angiography and glaucoma: where do we stand in 2021?
Wolf AT; Wolf AT
Acta Ophthalmologica 2022; 100: e377-e385

---

98596 Disease progression pathways of wet AMD: opportunities for new target discovery
Oddone F
Expert Opinion on Therapeutic Targets 2022; 26: 5-12

---

98167 Vascular biomarkers from optical coherence tomography angiography and glaucoma: where do we stand in 2021?
Harris A; Verticchio Vercellin A
Acta Ophthalmologica 2022; 100: e377-e385

---

98596 Disease progression pathways of wet AMD: opportunities for new target discovery
Siesky B; Verticchio Vercellin A
Expert Opinion on Therapeutic Targets 2022; 26: 5-12

---

98167 Vascular biomarkers from optical coherence tomography angiography and glaucoma: where do we stand in 2021?
Siesky B; Rowe LW
Acta Ophthalmologica 2022; 100: e377-e385

---

98596 Disease progression pathways of wet AMD: opportunities for new target discovery
Ciulla TA
Expert Opinion on Therapeutic Targets 2022; 26: 5-12

---

98167 Vascular biomarkers from optical coherence tomography angiography and glaucoma: where do we stand in 2021?
Rowe LW; Packles M; Oddone F
Acta Ophthalmologica 2022; 100: e377-e385

---